Latest profit margin for Conduit Pharmaceuticals: 12.94% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
The latest profit margin for CDT is 12.94% as of March 2026. That compares with 5.98% in the prior-year period — up 116.3% year over year. That is below the sector sector average of 19.72%. Investors often review this figure alongside Conduit Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Over the past year, CDT's profit margin moved from 5.98% to 12.94% — a 116.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Conduit Pharmaceuticals's valuation or profitability profile.
Against its sector companies, CDT currently prints 12.94% for profit margin, while the sector average sits near 19.72%. That is roughly 34.4% below the sector mean. Large gaps often invite a closer look at Conduit Pharmaceuticals's growth, margins, and balance sheet.
Profit Margin shows how effectively Conduit Pharmaceuticals converts resources into returns. At 12.94%, CDT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 5.98% in the prior-year period — up 116.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting CDT's profit margin (12.94%), review year-over-year change from 5.98%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.